They will get sued if they ever said in public. Automated or semi automated production is not necessary for FDA application. KITE which was approved by FDA several years ago could only produce 100 doses for patients in the first year. Volume is not important, its the quality control that FDA cares about with innovative and expensive personalized cellular therapies. They would never put that burden on companies.
The reason why they have stalled FDA application is because they are waiting on more data to mature via combo trial and such. This lack of disclosure to shareholders over the years along with other lies and dangling of carrots is going to land them in legal trouble later this year.
Market Data 
Markets 
AI
